IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study
The purpose of this study is to assess HIV remission among HIV-infected neonates who initiate ART within 48 hours of birth. For purposes of this protocol, remission is defined as having no confirmed plasma HIV RNA>=LOD for 48 weeks following ART cessation. Additional aim for the study is to assess the safety of very early ART in neonates. Also, to evaluate immune activation and host and viral determinants, including maternal factors and HIV-specific immune responses, associated with HIV remission.
KeywordsHIV-INFECTED, REMISSION, plasma, persistence, LPV exposures
Principal InvestigatorMobeen Rathore
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.